A new study finds that the hormone FGF21 is stimulated by fructose ingestion
BOSTON - Increased consumption of table sugar and high-fructose corn syrup has been linked to rising rates of obesity and type 2 diabetes in the United States and throughout the world. Both sweeteners are commonly found in processed foods and sugar-sweetened beverages, and both are made up of nearly equal amounts of two basic sugars, glucose and fructose.
The effects of glucose ingestion in humans are well understood, in part, because they are easily assessed by performing a Glucose Tolerance Test, which measures serum glucose levels after glucose ingestion and has become the diagnostic cornerstone for modern diabetes care. Furthermore, the hormone insulin can also be easily measured to assess the acute metabolic effects of glucose ingestion and evaluate a person's risk for developing diabetes and cardiovascular disease.
But determining the body's metabolic response to fructose has been much more difficult, and consequently, there is no equivalent test to warn of impaired or altered fructose metabolism.
That may soon change. A new study led by investigators at Beth Israel Deaconess Medical Center (BIDMC) now finds that blood levels of the hormone Fibroblast Growth Factor 21 (FGF21) increases rapidly acutely and robustly after fructose ingestion. Reported online in Molecular Metabolism, the new findings suggest that FGF21 is a reliable predictor of altered fructose metabolism and, in essence, provides the basis for a "Fructose Tolerance Test."
"Accumulating evidence suggests that the fructose component of sugar may have a particularly deleterious effect on health," explains co-senior author Mark Herman, MD, of the Division of Endocrinology, Diabetes and Metabolism at BIDMC and Assistant Professor of Medicine at Harvard Medical School (HMS). "If you feed animals or people higher-than-normal amounts of fructose, they become obese, less responsive to the key actions of insulin, and develop fatty liver disease and abnormal blood lipid levels. All of these increase the risk of developing diabetes and cardiovascular disease." Fructose is a pervasive presence throughout our foods: high fructose corn syrup, for example, can be found in everything from processed cookies and sweets to seemingly healthy foods, such as yogurt.
"Fructose is taken up by the liver as soon as it's ingested and very little of it makes it to peripheral blood where it might be sampled and measured," adds co-senior author Eleftheria Maratos-Flier, MD, HMS Professor of Medicine in the Division of Endocrinology, Diabetes and Metabolism at BIDMC. "This makes it very hard to determine how an individual responds to fructose ingestion. Furthermore, there has, to date, been no known hormonal response to fructose in the way that the hormone insulin responds to glucose."
Maratos-Flier has been studying the FGF21 hormone for almost a decade and previously found that in both humans and animals, FGF21 levels are elevated in association with obesity, insulin resistance, and non-alcoholic fatty liver disease. Herman's work, meanwhile, had focused on a cellular factor, Carbohydrate Responsive-Element Binding Protein (ChREBP), which senses simple sugars and responds by activating cellular gene expression programs. Observations that fructose potently activates ChREBP in rodent livers and that ChREBP can regulate FGF21 expression suggested to Maratos-Flier and Herman the intriguing hypothesis that fructose ingestion might stimulate production of circulating FGF21 in people.
To test this hypothesis, the researchers, led by first author Jody Dushay, MD, HMS Instructor in Medicine, recruited 10 lean, healthy study subjects. They first tested the effect of glucose on FGF21 by giving volunteers a drink of 75 grams of glucose and measuring blood levels over the course of five hours. There was no immediate effect on FGF21 levels although modest changes in FGF21 were seen three to four hours later. In contrast, after ingesting 75 grams of fructose, FGF21 levels dramatically increased by an average of 400 percent - within only two hours.
"This tells us that fructose actively regulates FGF21 in humans," says Maratos-Flier. "The hormone-like response of FGF21 to fructose ingestion suggests that FGF21 might play an unanticipated role in regulating fructose metabolism. We were totally surprised by this dramatic effect because, to date, there has been no way of assessing the body's acute metabolic response to fructose ingestion. We haven't had a simple quick test like we have for glucose."
Furthermore, she adds, the findings demonstrated that the FGF21 response was exaggerated in subjects with metabolic disease, suggesting that either some aspect of fructose metabolism changes during the development of metabolic syndrome and/or there are innate differences in fructose metabolism among individuals and those with an exaggerated FGF21 response to fructose are predisposed to developing disease.
"For the first time, this provides an avenue for labs everywhere to easily study fructose metabolism in people," adds Herman. "This study provides a foundational observation for further investigation into the genetic and environmental determinants of an individual's metabolic response to fructose and this type of knowledge will be essential to develop personalized dietary recommendations as well as pharmacological strategies to prevent and treat cardiometabolic disease."
In addition to Herman, Maratos-Flier and Dushay, coauthors include BIDMC investigators Elena Toschi, MD, Emilie K. Mitten, BS, and ffolliott M. Fisher, PhD.
This work was supported by the JPB Foundation and the Harvard Catalyst/Harvard Clinical and Translational Science Grants 8UL1TR000170-05 and 1UL1TR001102-01. Drs. Herman and Maratos-Flier received support from from the National Institutes of Health: R01DK028082, P30DK057521 and R01DK100425.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and currently ranks third in National Institutes of Health funding among independent hospitals nationwide.
BIDMC is in the community with Beth Israel Deaconess Hospital-Milton, Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Plymouth, Anna Jaques Hospital, Cambridge Health Alliance, Lawrence General Hospital, Signature Healthcare, Beth Israel Deaconess HealthCare, Community Care Alliance, and Atrius Health. BIDMC is also clinically affiliated with the Joslin Diabetes Center and Hebrew Senior Life and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit https://www.bidmc.org.
